Aveanna Healthcare (NASDAQ:AVAH – Get Free Report) posted its quarterly earnings data on Thursday. The company reported $0.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.19 by $0.03, FiscalAI reports. The firm had revenue of $670.48 million during the quarter, compared to analysts’ expectations of $638.61 million. Aveanna Healthcare had a return on equity of 124.68% and a net margin of 10.37%.
Here are the key takeaways from Aveanna Healthcare’s conference call:
- Q2 revenue rose 13.7% to $670.5 million, while adjusted EBITDA increased 8% to $95.4 million, with year-over-year growth across all three operating segments.
- Aveanna raised 2026 guidance to revenue above $2.68 billion and adjusted EBITDA above $365 million, attributing the increase to core organic performance rather than the recently acquired Family First business.
- The company reported progress on reimbursement and payer initiatives, including seven state rate increases, 37 Private Duty Services preferred payer agreements, and a significant California pediatric nursing rate increase scheduled for January 2027. Aveanna also lifted its long-term organic growth targets for Private Duty Services to 5%–6% and Home Health and Hospice to 8%–10%.
- Management expects gross-margin percentages to remain broadly stable because reimbursement gains will largely be passed through to caregiver wages; it plans to raise California wages ahead of the January 2027 rate increase, creating potential near-term margin pressure. The company also remains highly leveraged, with approximately $1.48 billion of variable-rate debt, despite targeting leverage below 3x over time.
Aveanna Healthcare Trading Up 24.8%
NASDAQ AVAH opened at $11.29 on Friday. The firm has a market cap of $2.46 billion, a PE ratio of 9.57, a price-to-earnings-growth ratio of 0.90 and a beta of 1.90. Aveanna Healthcare has a 1-year low of $5.93 and a 1-year high of $11.54. The stock has a 50-day moving average of $8.86 and a 200-day moving average of $7.73. The company has a current ratio of 1.47, a quick ratio of 1.47 and a debt-to-equity ratio of 5.35.
Key Headlines Impacting Aveanna Healthcare
- Positive Sentiment: Quarterly results exceeded expectations. Aveanna reported adjusted earnings of $0.22 per share, above consensus estimates of approximately $0.17–$0.19, while revenue reached $670.5 million versus the $638.6 million consensus estimate. Revenue increased 13.7% year over year, and net income rose to $40.3 million from $27.0 million. Aveanna Healthcare second-quarter financial results
- Positive Sentiment: Management raised its 2026 financial targets. Full-year revenue guidance was increased to more than $2.68 billion from $2.63 billion–$2.65 billion, while adjusted EBITDA guidance rose to more than $365 million from $338 million–$342 million. Adjusted EBITDA for the quarter was $95.4 million, up 8% year over year. Aveanna Healthcare earnings call highlights
- Positive Sentiment: Analyst commentary was supportive. One analysis said the results reinforced its buy rating, citing Aveanna’s relatively low forward valuation and strong EBITDA margin compared with peers. The company’s Private Duty Services segment remains the main growth engine, accounting for roughly 83% of revenue. Aveanna Healthcare Q2 earnings analysis
- Neutral Sentiment: Investors are focusing on execution and the earnings-call outlook. The strong growth forecast supports the recent rally, but the stock’s valuation and elevated leverage may make it more sensitive to any slowdown in operating performance or guidance.
- Negative Sentiment: Gross-margin pressure remains a concern. Despite revenue growth, gross margins declined across Aveanna’s business segments. Continued margin compression could limit the benefit of higher revenue and make the upgraded EBITDA targets harder to sustain. Aveanna Healthcare Q2 2026 earnings call transcript
Insider Buying and Selling
In other Aveanna Healthcare news, major shareholder Paul R. Vigano sold 7,000,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $6.24, for a total value of $43,680,000.00. Following the completion of the sale, the insider owned 252,899 shares in the company, valued at approximately $1,578,089.76. The trade was a 96.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder J.H. Whitney Equity Partners V sold 5,842,240 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $6.24, for a total value of $36,455,577.60. Following the sale, the insider directly owned 13,450,547 shares of the company’s stock, valued at approximately $83,931,413.28. This trade represents a 30.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 31,305,664 shares of company stock valued at $215,555,910 in the last 90 days. 5.30% of the stock is owned by insiders.
Institutional Investors Weigh In On Aveanna Healthcare
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quantbot Technologies LP purchased a new stake in Aveanna Healthcare in the second quarter worth $43,000. Oxford Asset Management LLP purchased a new position in Aveanna Healthcare during the 2nd quarter valued at $64,000. Bayesian Capital Management LP purchased a new position in Aveanna Healthcare during the 2nd quarter valued at $85,000. Jain Global LLC bought a new position in Aveanna Healthcare in the 4th quarter worth $102,000. Finally, Invesco Ltd. raised its holdings in Aveanna Healthcare by 31.1% in the 2nd quarter. Invesco Ltd. now owns 20,006 shares of the company’s stock worth $105,000 after purchasing an additional 4,742 shares in the last quarter. 87.96% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
AVAH has been the subject of a number of recent research reports. Weiss Ratings restated a “hold (c+)” rating on shares of Aveanna Healthcare in a research report on Thursday, July 2nd. Barclays increased their price target on shares of Aveanna Healthcare from $9.00 to $9.50 and gave the company an “overweight” rating in a research report on Thursday, July 9th. Truist Financial lifted their price target on shares of Aveanna Healthcare from $9.00 to $11.00 and gave the stock a “hold” rating in a research note on Tuesday, July 14th. Stephens upgraded shares of Aveanna Healthcare from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $10.00 to $11.00 in a report on Friday, May 15th. Finally, Royal Bank Of Canada raised shares of Aveanna Healthcare from a “sector perform” rating to an “outperform” rating and set a $10.00 price objective for the company in a research note on Wednesday, June 3rd. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $10.78.
Get Our Latest Analysis on AVAH
Aveanna Healthcare Company Profile
Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.
In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.
Featured Stories
- Five stocks we like better than Aveanna Healthcare
- Why Are Analysts Freaking Out About Apple’s All-Glass iPhone?
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
Receive News & Ratings for Aveanna Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aveanna Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
